drugdeliverybusiness7d
Vivani Medical initiates first-in-human GLP-1-eluting implant study
Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP ...
Ukrainska Pravda on MSN8d
Zelenskyy: Ukraine does not yet have the strength to liberate Crimea and Donbas
President Volodymyr Zelenskyy has said that Ukraine does not yet have the strength to liberate occupied Crimea and part of ...
Benzinga.com7d
EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia
Vivani Medical began the LIBERATE-1 trial, testing a six-month exenatide implant for chronic weight management in Australia. The study uses NanoPortal technology, with results expected in mid-2025 and ...
Vivani股票因exenatide植入剂LIBERATE-1临床试验进展引起关注
名为LIBERATE-1的试验正在澳大利亚进行，标志着Vivani专有NanoPortal™药物植入技术的首次应用。该试验旨在评估exenatide植入剂在超重或肥胖参与者中的安全性、耐受性和药代动力学特征，以体重变化作为主要衡量指标。